Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation
Gero Hütter, Daniel Nowak, Maximilian Mossner, Susanne Ganepola, Arne Müssig, Kristina Allers, Thomas Schneider, Jörg Hofmann, Claudia Kücherer, Olga Blau, Igor W Blau, Wolf K Hofmann, Eckhard Thiel, Gero Hütter, Daniel Nowak, Maximilian Mossner, Susanne Ganepola, Arne Müssig, Kristina Allers, Thomas Schneider, Jörg Hofmann, Claudia Kücherer, Olga Blau, Igor W Blau, Wolf K Hofmann, Eckhard Thiel
Abstract
Infection with the human immunodeficiency virus type 1 (HIV-1) requires the presence of a CD4 receptor and a chemokine receptor, principally chemokine receptor 5 (CCR5). Homozygosity for a 32-bp deletion in the CCR5 allele provides resistance against HIV-1 acquisition. We transplanted stem cells from a donor who was homozygous for CCR5 delta32 in a patient with acute myeloid leukemia and HIV-1 infection. The patient remained without viral rebound 20 months after transplantation and discontinuation of antiretroviral therapy. This outcome demonstrates the critical role CCR5 plays in maintaining HIV-1 infection.
2009 Massachusetts Medical Society
Source: PubMed